ASO Author Reflections: Organoid Model to Aid the Decision of Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
ASO Author Reflections: Organoid Model to Aid the Decision of Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer ; day:20 ; month:11 ; year:2024 ; pages:1-2
Annals of surgical oncology ; (20.11.2024), 1-2
- Urheber
-
Liu, Duo
Yang, Keli
Cai, Jian
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-024-16555-4
- URN
-
urn:nbn:de:101:1-2502062152370.838536346303
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liu, Duo
- Yang, Keli
- Cai, Jian
- SpringerLink (Online service)
Ähnliche Objekte (12)
ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?
ASO Author Reflections: A Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
ASO Author Reflections: Changes in Coagulation Biomarkers and the Risk for Venous Thromboembolism After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
ASO Author Reflections: First Do No Harm—Revisiting Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Trials to Reduce the Risk of Peritoneal Metastasis
ASO Author Reflections: Addressing Hospital-Based Disparities in Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) and Survival in Patients with Isolated Colorectal Peritoneal Metastases
Influence of hyperthermic intraperitoneal chemotherapy on renal blood perfusion
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC)
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?
Robotic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is there a benefit?
Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?
ASO Author Reflections: A Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
ASO Author Reflections: Changes in Coagulation Biomarkers and the Risk for Venous Thromboembolism After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
ASO Author Reflections: First Do No Harm—Revisiting Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Trials to Reduce the Risk of Peritoneal Metastasis
ASO Author Reflections: Addressing Hospital-Based Disparities in Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) and Survival in Patients with Isolated Colorectal Peritoneal Metastases
Influence of hyperthermic intraperitoneal chemotherapy on renal blood perfusion
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC)
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?
Robotic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is there a benefit?
Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?
ASO Author Reflections: A Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
ASO Author Reflections: Changes in Coagulation Biomarkers and the Risk for Venous Thromboembolism After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
ASO Author Reflections: First Do No Harm—Revisiting Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Trials to Reduce the Risk of Peritoneal Metastasis
ASO Author Reflections: Addressing Hospital-Based Disparities in Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) and Survival in Patients with Isolated Colorectal Peritoneal Metastases
Influence of hyperthermic intraperitoneal chemotherapy on renal blood perfusion
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC)
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?
Robotic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is there a benefit?